Our Executive Chairman, Giedrius Kalesnykas, and CBO, Guillaume Demarne will be attending this key industry event from March 25–27, 2025, where leading experts will come together to advance the future of gene therapy.

With ocular gene therapies gaining momentum, Experimentica is at the forefront, providing:
· Specialized ocular models to assess gene therapy efficacy and safety.
· Advanced imaging, histology, and biomolecular analysis to generate precise, high-impact data.

If you are developing gene therapies for ophthalmic indications and want to discuss how our expertise can accelerate your research, let’s connect! Reach out to schedule a meeting in Boston.